Context Therapeutics (NASDAQ:CNTX) Upgraded to Strong-Buy at Citizens Jmp

Context Therapeutics (NASDAQ:CNTX) was upgraded by Citizens Jmp to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

Other equities analysts have also recently issued reports about the company. JMP Securities initiated coverage on Context Therapeutics in a research note on Wednesday. They issued an “outperform” rating and a $4.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Context Therapeutics in a report on Monday, September 23rd. Finally, D. Boral Capital initiated coverage on shares of Context Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $9.00 price objective for the company. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Context Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $6.33.

Context Therapeutics Trading Up 11.0 %

Shares of NASDAQ CNTX opened at $1.21 on Wednesday. The business has a 50-day moving average of $1.52 and a 200-day moving average of $1.94. The firm has a market capitalization of $90.75 million, a price-to-earnings ratio of -1.33 and a beta of 2.10. Context Therapeutics has a 12 month low of $0.89 and a 12 month high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). On average, analysts predict that Context Therapeutics will post -0.51 earnings per share for the current year.

Institutional Trading of Context Therapeutics

Hedge funds have recently modified their holdings of the business. Driehaus Capital Management LLC bought a new stake in Context Therapeutics during the second quarter worth about $4,527,000. Great Point Partners LLC purchased a new stake in shares of Context Therapeutics in the 2nd quarter worth approximately $14,876,000. Blue Owl Capital Holdings LP bought a new position in Context Therapeutics during the 2nd quarter valued at approximately $10,348,000. State Street Corp raised its stake in Context Therapeutics by 21.5% during the third quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after buying an additional 19,800 shares during the last quarter. Finally, Nantahala Capital Management LLC bought a new position in shares of Context Therapeutics in the second quarter worth approximately $3,881,000. Institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.